FindTrial
Sign In

COMPARISION OF EFFICACY OF BROMELAIN AND ACECLOFENAC IN REDUCING POST-OPERATIVE COMPLICATIONS AFTER THIRD MOLAR SURGERY

COMPARISION OF EFFECT OF BROMELAIN AND ACECLOFENAC ON POST-OPREATIVE SEQUELAE FOLLOWING SURGICAL REMOVAL OF IMPACTED MANDIBULAR THIRD MOLAR

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031510
Enrollment
72
Registered
2021-02-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K011- Impacted teeth

Interventions

Intervention1: BROMELAIN: TAB. BROMELAIN 500 MG BD ORALLY FOR 4 DAYS Control Intervention1: ACECLOFENAC: TAB. ACECLOFENAC 250 MG BD ORALLY FOR 3 DAYS

Sponsors

AISHWARYA GUPTA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having impacted third molar. A medical history devoid of any systemic pathological condition A medical history devoid of any pharmacological therapy able to introduce variables into the experiment and no periodontal diseases affecting contiguous teeth

Exclusion criteria

Exclusion criteria: 1) Acute infection in relation to third molar 2) Patient having Pine-apple allergy. 3) Periapical pathology 4) Severe periodontal disease 5) Uncontrolled systemic diseases. 6) Debilitating disease.

Design outcomes

Primary

MeasureTime frame
BROMELAIN IS MORE EFFIACIOUS THAN ACECLOFENAC IN CONTROLLING POST-OPERATIVE SEQUALAE FOLLOWING THIRD MOLAR SURGERYTimepoint: FIRST, FIFTH AND SEVENTH DAY AFTER THIRD MOLAR SURGERY—

Secondary

MeasureTime frame
BROMELAIN IS MORE EFFICACIOUS THAN ACECLOFENAC IN REDUCING POST-OPERATIVE PAIN AND EDEMA FOLLOWING THIRD MOLAR SURGERYTimepoint: FIRST, FIFTH AND SEVENTH DAY—

Countries

India

Contacts

Public ContactAISHWARYA GUPTA

DMIMS

rajanikanthmalaviya@gmail.com8380993550

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026